ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012 Financial Results
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
host a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Monday, February 25, 2013. Harvey J. Berger, M.D., chairman and chief
executive officer, will host the call. Senior management will discuss
the Company’s financial results as of December 31, 2012, key corporate
objectives and additional corporate activities. The Company will
announce the highlights of these topics in a press release to be issued
before the market opens on February 25, 2013 prior to the conference
call.
The live webcast can be accessed by visiting the investor relations
section of the Company’s website at http://investor.ariad.com.
The call can be accessed by dialing 866-831-6272 (domestic) or
617-213-8859 (international) five minutes prior to the start time and
providing the pass code 59632303. A replay of the call will be available
on the ARIAD website approximately two hours after completion of the
call and will be archived for three weeks.
About ARIAD
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform
the lives of cancer patients. ARIAD’s first medicine, Iclusig™, is
approved in the U.S. for the treatment of adult patients with chronic,
accelerated or blast phase chronic myeloid leukemia that is resistant or
intolerant to prior tyrosine kinase inhibitor (TKI) therapy or
Philadelphia chromosome-positive acute lymphoblastic leukemia that is
resistant or intolerant to prior TKI therapy. Additional clinical trials
of Iclusig in other cancers are ongoing. ARIAD is also studying AP26113,
another molecularly targeted medicine, in certain forms of lung cancer.
For additional information, visit http://www.ariad.com
or follow ARIAD on Twitter (@ARIADPharm).
